LifeMap Sciences

What LifeMap Sciences does

LifeMap Sciences is a private biomedical data-infrastructure company that operates the GeneCards Suite, an integrated knowledge platform originally developed at the Weizmann Institute of Science (Israel) beginning in 1998 and commercialized by LifeMap since 2003. The core asset is the GeneCards Knowledge Graph, which unifies >190 authoritative biomedical databases into a single graph containing 173M+ relationships across genes, proteins, diseases, compounds, pathways, variants, and clinical trials, with standardized identifiers across 50 namespaces and 13.8M cross-references. The Suite exposes five research products — GeneCards (471K+ genes), MalaCards (22,800 diseases), PathCards (pathways), GeneAnalytics (gene-set enrichment), and VarElect (variant prioritization, used in 100,000+ exome/genome diagnoses) — distributed in five delivery formats (Relational DB, Neo4j, JSON, KGX, REST API).

The company serves a dual market. Academic researchers, hospital clinicians, and individual scientists receive free access (4.5M+ researchers, 10,000+ institutions, 150+ countries) and drive citation-based brand strength (15K+ peer-reviewed citations). Commercial customers — 18.2+ named enterprises including Amgen, Sanofi, GSK, Genentech, Bristol-Myers Squibb, Valo Health, Accenture, USPTO, EPO, and EveryCure — pay subscription-based fees for production data licensing, multi-format delivery, and custom integration support. A third revenue stream monetizes the researcher audience through an advertising platform (gene-targeted product listings and CPM banner ads) reaching life science advertisers such as Abcam, Bio-Techne, Sino Biological, and OriGene. The company is headquartered in California with R&D in Rehovot, Israel (co-located with the Weizmann Institute) and a regional office in Hong Kong; reported headcount is 1–10 employees and no external funding rounds are disclosed.

Name

LifeMap Sciences

Legal name

LifeMap Sciences, Inc.

Website

http://www.lifemapsc.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

LifeMap Sciences operates the GeneCards Suite, a biomedical knowledge graph integrating >190 sources with 173M+ relationships, serving 4.5M+ academic researchers for free and licensing enterprise data packages to pharma, biotech, AI, and government customers.

Ownership category

akta.pro rank

Product category

Biomedical Knowledge Graph Software

NAICS

Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

Keywords

• Biomedical knowledge graph
• Gene database software
• Variant prioritization tools
• Enterprise data licensing
• Life sciences advertising

Headquarters

HQ city

Walnut

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Enterprise Data Licensing: Commercial licensing of Knowledge Graph data packages for production use at pharma, biotech, diagnostic, and AI companies. Provides relational DB, Neo4j, JSON, KGX, and API access. Subscription-based with custom integration support.
2. GeneCards Suite Advertising: Gene-targeted product listings and banner display advertising reaching 5M+ researchers at 10,000+ institutions. Sold on CPM basis for banner ads and per-product for listings. Multi-year renewals from major life science advertisers.
3. Premium Tools Subscription: Subscription access to GeneCards Suite Premium Tools including VarElect (variant prioritization), GenesLikeMe, GeneAnalytics (gene set analysis), and GeneALaCart. Free trial available; commercial and academic licensing options.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

LifeMap Sciences develops and commercializes the GeneCards Suite, an integrated biomedical knowledge platform that unifies over 190 research databases into a single queryable knowledge graph with 173M+ relationships connecting genes, diseases, drugs, pathways, and variants. The company offers free academic access to five research tools (GeneCards, MalaCards, PathCards, GeneAnalytics, VarElect) while monetizing enterprise data licensing, premium tool subscriptions, and gene-targeted advertising.

Product overview

LifeMap Sciences offers the GeneCards Suite, a platform built on a unified knowledge graph that integrates >190 biomedical sources into five interconnected research tools: GeneCards (human gene database with 471K+ genes), MalaCards (human disease database with 22,800 disorders), PathCards (unified pathway database), GeneAnalytics (gene set enrichment analysis), and VarElect (variant prioritization). The underlying GeneCards Knowledge Graph contains 173M+ relationships connecting genes, diseases, compounds, pathways, variants, and more. The suite serves 4.5M+ researchers globally with free academic access and commercial enterprise licensing.

Differentiator

Problem solved

Functional benefit

Brands

• GeneCards: The human gene database - the most comprehensive human gene database integrating data from over 190 sources with interactive visualization, AI summaries, and powerful search across 471K+ genes.
• MalaCards
• GeneCards Knowledge Graph
• PathCards
• GeneAnalytics
• VarElect

Products and services

• GeneCards The most comprehensive human gene database integrating 471K+ genes from over 190 sources with interactive visualization, AI-generated summaries for 21K+ protein-coding genes, variant dashboards, protein structure viewers (including AlphaFold models), expression heatmaps, and cross-referenced identifiers. Available free for academic and clinical use.
• MalaCards The human disease database integrating 22,800 disorders from 78 curated sources with gene associations, drugs, variations, phenotypes, and pathways. Features 16 richly annotated sections per disease card and AI-supported disease summaries.
• PathCards Unified human biological pathways database that consolidates overlapping pathways from multiple sources into integrated SuperPaths for streamlined pathway analysis.
• GeneAnalytics Gene set analysis tool that translates gene lists into biological insights through enrichment analysis across pathways, diseases, tissues, compounds, and more.
• VarElect Variant prioritization tool that leverages the GeneCards knowledgebase to rank genomic variants by phenotype for clinical and research use. Has been used in diagnosis of 100,000+ exome and whole genome cases.
• GeneCards Knowledge Graph The underlying integrated knowledge graph powering the GeneCards Suite containing 173M+ relationships connecting genes, proteins, diseases, compounds, pathways, variants, and more from over 190 sources. Available for licensing in relational DB, Neo4j, JSON, KGX, and API delivery formats for enterprise AI and research pipelines.
• GeneCards Suite Integrated platform combining five research tools (GeneCards, MalaCards, PathCards, GeneAnalytics, VarElect) built on a unified knowledge graph. Offers free academic access and commercial licensing for enterprise use.
• GeneCards Advertising Advertising service reaching 5M+ researchers annually across 10,000+ institutions in 150+ countries. Offers gene-targeted product listings and banner display advertising with real-time campaign metrics.

Quantifiable outcome

• Researchers worldwide: 4.5M+
• +5 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

One partnership is on record.

• Weizmann Institute of SciencecoreStrategic or Co-development PartnerOriginal development partner for GeneCards starting in 2003. GeneCards was created at the Weizmann Institute in Rehovot, Israel as an academic project. LifeMap partnered with the Institute to commercialize and expand the platform. R&D operations remain in Israel co-located with the Institute.

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Open Targets Platform: Open Targets is a public-private partnership (GSK, Sanofi, Wellcome, EMBL-EBI) that integrates genetics, omics, chemistry, and drug data for systematic drug target identification and prioritization. It is a direct competitor in biomedical data integration for pharma R&D, with similar AI/RAG relevance but backed by major pharma funding.
• BenchSci: BenchSci applies AI to biomedical literature and reagent data to accelerate preclinical research, serving pharma scientists with antibody and experiment recommendations. It overlaps with LifeMap's researcher-targeted intelligence tools and shares the same advertising/monetization angle toward life science vendors.
• Molecular Connections: Molecular Connections provides curated life science data, knowledge graphs, and text-mining services for pharma R&D. It is directly comparable to LifeMap's Knowledge Graph and MalaCards disease intelligence offerings, particularly for literature mining and target-disease relationships.

Broad incumbents

• EMBL-EBI (European Bioinformatics Institute): EMBL-EBI hosts many of the underlying databases LifeMap integrates (UniProt, Ensembl, ChEMBL, Expression Atlas). It is a broad incumbent offering a portfolio of life science data services and serves as both a data source for LifeMap and a potential long-term competitor for integrated knowledge products.
• NCBI (National Center for Biotechnology Information): NCBI provides free access to gene, literature, and biomedical data (Gene, PubMed, dbSNP, ClinVar). As a government-funded incumbent, it underpins much of LifeMap's data sources and competes for researcher attention with free, authoritative alternatives.
• DNAnexus: DNAnexus provides a cloud-based genomics and biomedical data platform serving pharma, clinical labs, and consortia. It overlaps with LifeMap on enterprise biomedical data integration and AI/clinical pipelines but with broader scope and significantly more funding.
• Clarivate (Cortellis / Drug Discovery): Clarivate's life sciences portfolio (Cortellis, Drug Discovery, BioWorld) provides integrated drug, clinical trial, and biomedical intelligence to pharma enterprises. It competes with LifeMap in the enterprise data-licensing segment and is significantly larger and broader.
• Tempus Labs: Tempus integrates molecular and clinical data at scale for precision medicine and pharma R&D. While primarily clinical/oncology focused, it competes with LifeMap for pharma enterprise data-licensing budgets and offers similarly structured data products for AI workflows.

Emerging players

• Owkin: Owkin applies federated AI to biomedical and clinical data for pharma research. It is an emerging player with partial overlap on LifeMap's enterprise AI/data licensing offerings, especially around AI-ready biomedical data integration for pharma pipelines.
• BioRender: BioRender provides scientific illustration and figure tools for life science researchers, monetized via subscriptions. It shares LifeMap's PLG, researcher-focused GTM and advertising adjacency (selling to life science vendors), making it a relevant comparable for the freemium-to-paid researcher model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeMap Sciences